AVLN financial statements
The full income statement, balance sheet, and cash-flow statement for Avalyn Pharma Inc. (AVLN), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
| Line item | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| Income Statement | as ofJun 30 ’26 | as ofMar 31 ’26 | |
| 31.3M | 27.9M | ||
| Research & development | 24.7M | 22.9M | |
| Selling, general & administrative | 6.56M | 5.02M | |
| General & administrative | 6.56M | 5.02M | |
| Operating income | -31.3M | -27.9M | |
| Interest expense | 272K | 98.0K | |
| Interest & investment income | 2.70M | 1.13M | |
| Other non-operating income | -69.0K | 13.0K | |
| Gain (loss) on equity securities | -107K | -122K | |
| Income tax | — | 0.00 | |
| -28.9M | -26.9M | ||
| Net income to common | -28.9M | -26.9M | |
| -$0.98 | -$21.83 | ||
| EPS (basic) | -$0.98 | -$21.83 | |
| Weighted-avg shares (basic) | 29.7M | 1.23M | |
| Weighted-avg shares (diluted) | 29.7M | 1.23M | |
| Balance Sheet | as ofJun 30 ’26 | as ofMar 31 ’26 | |
| 358M | 130M | ||
| Cash & equivalents | 264M | 92.3M | |
| Short-term investments | 88.2M | 30.8M | |
| Prepaid expenses | 5.56M | 6.86M | |
| 425M | 136M | ||
| Property, plant & equipment | 1.21M | 1.26M | |
| Operating lease right-of-use | 2.14M | 1.42M | |
| Long-term investments | 61.1M | — | |
| Other non-current assets | 3.01M | 3.00M | |
| Total non-current assets | 67.5M | 5.68M | |
| 10.8M | 11.8M | ||
| Accounts payable | 2.65M | 3.15M | |
| Accrued liabilities | 7.34M | 8.13M | |
| Current lease liability | 816K | 507K | |
| 27.1M | 27.7M | ||
| Long-term debt | 14.8M | 14.8M | |
| Non-current lease liability | 1.49M | 1.09M | |
| Operating lease liability (total) | 2.31M | 1.60M | |
| 398M | -264M | ||
| Preferred stock | 0.00 | — | |
| Common stock | 67.0K | 24.0K | |
| Additional paid-in capital | 720M | 27.9M | |
| Retained earnings | -321M | -292M | |
| Accumulated other comprehensive income | -95.0K | 12.0K | |
| Total liabilities & equity | 425M | 136M | |
| Common shares issued | 44.3M | 1.23M | |
| Common shares outstanding | 44.3M | 1.23M | |
| Shares outstanding (cover) | 44.3M | 44.3M | |
| Cash Flow | as ofJun 30 ’26 | as ofMar 31 ’26 | |
| -26.1M | -29.9M | ||
| Depreciation & amortization | 110K | 63.0K | |
| Share-based compensation | 2.79M | 1.19M | |
| Change in payables | -93.0K | -1.11M | |
| -119M | 55.0M | ||
| Capital expenditure | 269K | 318K | |
| Free cash flow | -26.3M | -30.2M | |
| Acquisitions | 0.00 | 0.00 | |
| 317M | 14.9M | ||
| Long-term debt issued | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | |
| Common stock issued | -50.0M | 50.0M | |
| Common stock repurchased | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | |
| Valuation Ratios | as ofJun 30 ’26 | as ofMar 31 ’26 | |
| Market cap | 1.46B | — | |
| P/B | 3.7× | — | |
| Source filing | 10-Q | 10-Q |
About this data
Source: AVLN’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all AVLN filings on SEC EDGAR → Not investment advice.